Last reviewed · How we verify
JNJ-64251330
At a glance
| Generic name | JNJ-64251330 |
|---|---|
| Also known as | Lorpucitinib |
| Sponsor | Janssen Research & Development, LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of JNJ-64251330 in Participants With Familial Adenomatous Polyposis (PHASE1)
- A Study of JNJ-64251330 in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |